About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clinical trials are needed to develop new medicines for children and teens living with seizures

By: Brandpoint

(BPT) - Epilepsy at any age can be challenging to navigate, even more so when a patient is a young child or teen. Some medications can help manage seizures for many patients. However, one-third of children with newly diagnosed epilepsy fail the first antiseizure medication they were prescribed. These patients may experience seizures even when taking their medications as prescribed.

The impact of seizures on children and teens

Seizures may be a frightening experience for a child. When their symptoms can't be controlled by medication, pediatric patients with seizures can develop lifelong challenges.

'I've witnessed firsthand the negative impact seizures can have on the quality of life of children and teens,' said Sunita Misra, M.D., Ph.D., and chief medical officer at SK Life Science, a company that develops treatments for seizure disorders.

During her career, Dr. Misra has cared for drug-resistant pediatric epilepsy patients. 'When traditional medications are unsuccessful in managing seizures, young patients and their families must contend with health challenges that affect a child's ability to thrive academically, socially and emotionally," explained Dr. Misra.

For young children, seizures may disrupt a child's brain development, which can lead to a serious impact on their lives. According to the Epilepsy Foundation, seizures can stymie a child's academic achievements and lead to emotional and behavioral issues.

Also, because seizures aren't predictable, a child may experience anxiety and distress, preventing them from fully engaging in school and social activities. The unpredictability can also be challenging for caregivers to maintain jobs, impacting the financial well-being of families, which can cause more anxiety for a child and their loved ones.

Teens living with seizure disorders can feel left out when it comes to adolescent milestones. For example, getting a driver's license is a rite of passage, representing independence, maturity and freedom. Adolescents contending with uncontrolled seizures generally cannot obtain their license, which can make them feel left out, isolated from their peers and dependent on others.

How clinical trials may help

Researchers are constantly conducting studies to try to develop new or improved treatments that can address the unmet needs of pediatric patients living with seizures.

For example, SK Life Science is currently enrolling patients in three clinical trials investigating a potential treatment for teens with primary generalized tonic-clonic (PGTC) seizures and young children with partial-(focal) onset seizures.

The PGTC clinical trial is a global Phase 3 study activated in the U.S. as well as 11 other countries. This trial recruits pediatric patients between the ages of 12 and 17 who continue to have PGTC seizures despite traditional medications.

The remaining two trials focus on pediatric partial-onset seizures. The Phase 1 trial is an open-label pharmacokinetics study that is currently recruiting patients between the ages of 2 to 5 in the U.S., South Korea, Hungary and Spain. Meanwhile, the Phase 3 trial is an open-label safety study also recruiting in the U.S., South Korea, Hungary and Spain, as well as Australia and Poland.

'At SK Life Science, we are currently working to provide alternatives for younger patients,' said Dr. Misra. 'If you are a parent of an adolescent diagnosed with PGTC or of a toddler or young child with partial-onset seizures, you may want to speak with your doctor to see if your child can participate in these trials.' To learn more, visit www.sklifescienceinc.com.

More News

View More
3 Heavily Shorted Stocks That Could Pop on Rate Cuts
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers ETSY SMR SOUN
Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
Via MarketBeat
Tickers AVGO META
PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Via MarketBeat
Tickers PEP
Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been
Via MarketBeat
Tickers DKNG
Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom
Via MarketBeat
Tickers BUD STZ
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.